RLM - Realm Therapeutics Plc

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Realm Therapeutics Plc

267 Great Valley Parkway
Malvern, PA 19355
United States
484-321-2700
http://www.realmtx.com

SectorIndustrials
IndustryConglomerates
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. John Alexander MartinCEO & Exec. Director435.85kN/A1968
Ms. Marella ThorellCFO, COO, Company Sec. & Exec. Director364.98kN/A1967
Dr. Christian PetersChief Medical OfficerN/AN/A1962
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Realm Therapeutics plc does not have significant operations. It intends to invest in, partner with, acquire, and/or be acquired by a company with development potential in the life sciences sector or other business prospects. Previously, it was engaged in developing therapies for the treatment of immune mediated diseases in adults and children. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics plc in December 2016. Realm Therapeutics plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.

Corporate Governance

Realm Therapeutics Plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.